{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:23:46Z","timestamp":1790796226626,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.pharma.2018.07.005","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T19:07:28Z","timestamp":1535051248000},"page":"499-503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Maladie de Berger au cours d\u2019une Polyarthrite Rhumato\u00efde trait\u00e9e par Adalimumab"],"prefix":"10.1016","volume":"76","author":[{"given":"A.","family":"Pierrot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Combe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lepelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Constant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.pharma.2018.07.005_bib0090","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.pharma.2018.07.005_bib0095","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/rheumatology\/keu339","article-title":"Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice","volume":"54","author":"Fortunet","year":"2015","journal-title":"Rheumatol Oxf Engl"},{"issue":"6","key":"10.1016\/j.pharma.2018.07.005_bib0100","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jbspin.2013.05.003","article-title":"Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept","volume":"80","author":"Michel","year":"2013","journal-title":"Jt Bone Spine Rev Rhum"},{"issue":"5","key":"10.1016\/j.pharma.2018.07.005_bib0105","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.berh.2014.10.001","article-title":"Adverse effects of TNF inhibitors in SpA: are they different from RA?","volume":"28","author":"Sampaio-Barros","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.pharma.2018.07.005_bib0110","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-4632.2011.04871.x","article-title":"TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists","volume":"50","author":"Williams","year":"2011","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.pharma.2018.07.005_bib0115","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/jcpt.12506","article-title":"A case of lupus-like syndrome in a patient receiving adalimumab and a brief review of the literature on drug-induced lupus erythematosus","volume":"42","author":"Lomicov\u00e1","year":"2017","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.pharma.2018.07.005_bib0120","first-page":"812781","article-title":"Adalimumab (TNF \u03b1 Inhibitor) Therapy Exacerbates IgA Glomerulonephritis Acute Renal Injury and Induces Lupus Autoantibodies in a Psoriasis Patient","volume":"2013","author":"Wei","year":"2013","journal-title":"Case Rep Nephrol"},{"issue":"7","key":"10.1016\/j.pharma.2018.07.005_bib0125","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","article-title":"Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis","volume":"20","author":"Stokes","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.pharma.2018.07.005_bib0130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ibd.21370","article-title":"Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent","volume":"17","author":"Subramanian","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.pharma.2018.07.005_bib0135","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5114\/pdia.2015.53320","article-title":"Autoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritis","volume":"32","author":"Pirowska","year":"2015","journal-title":"Postepy Dermatol Alergol"},{"issue":"4","key":"10.1016\/j.pharma.2018.07.005_bib0140","first-page":"137","article-title":"Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis","volume":"61","author":"den Broeder","year":"2003","journal-title":"Neth J Med"},{"issue":"10","key":"10.1016\/j.pharma.2018.07.005_bib0145","first-page":"1885","article-title":"Tumor necrosis factor-alpha blockade and the risk of vasculitis","volume":"31","author":"Guillevin","year":"2004","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.pharma.2018.07.005_bib0150","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.pharma.2018.07.005_bib0155","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/rheumatology\/36.11.1189","article-title":"Mesangial glomerulonephritis as an extra-articular manifestation of rheumatoid arthritis","volume":"36","author":"Korpela","year":"1997","journal-title":"Br J Rheumatol"},{"issue":"3","key":"10.1016\/j.pharma.2018.07.005_bib0160","first-page":"154","article-title":"Analysis of renal pathology and drug history in 158\u00a0Japanese patients with rheumatoid arthritis","volume":"50","author":"Nakano","year":"1998","journal-title":"Clin Nephrol"},{"issue":"8","key":"10.1016\/j.pharma.2018.07.005_bib0165","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.autrev.2014.05.005","article-title":"Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort","volume":"13","author":"Piga","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.pharma.2018.07.005_bib0085","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000345091830110X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000345091830110X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:33:30Z","timestamp":1757720010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000345091830110X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S000345091830110X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2018.07.005","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maladie de Berger au cours d\u2019une Polyarthrite Rhumato\u00efde trait\u00e9e par Adalimumab","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2018.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS on behalf of Acad\u00e9mie Nationale de Pharmacie.","name":"copyright","label":"Copyright"}]}}